Diabetic macular oedema

Eye
#Diabetic macular oedema

Positive results in Phase II trial of migaldendranib for DMO and nAMD

Ashvattha Therapeutics has announced positive results in the Phase II trial of migaldendranib (MGB), a targeted nanomedicine for the treatment of diabetic macular oedema (DMO) and neovascular age-related macular degeneration (nAMD).  The findings showed the annualised rate of IVT injections in all study eyes decreased from 8.4… Read More

#News

Diabetic eye disease
#Breye Therapeutics #Diabetes #Diabetic macular oedema #Ophthalmology #Phase I trial

Phase Ib trial complete in patients with diabetic retinopathy

Breye Therapeutics is a clinical-stage ophthalmology focused biopharmaceutical company developing oral therapeutics for the early treatment of vascular eye diseases. The company has now completed its Phase Ib clinical trial evaluating its lead candidate, danegaptide, in patients with non-proliferative diabetic retinopathy (NPDR) with associated oedema. Read More

#News

#Biopharmaceuticals #Clinical trials #Diabetes #Diabetic macular oedema #Eye health #Retinopathy

Investigating potential for an oral treatment in diabetic retinopathy  

Breye Therapeutics, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, has started a Phase Ib/IIa clinical trial to investigate danegaptide, following oral administration, in patients suffering from diabetic macular oedema (DMO).  Breye is developing novel, oral ophthalmology drugs fordiabetic retinopathy (DR)… Read More

#News